The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis

American Journal of Kidney Diseases

Volumn 68, Issue 4, 2016, Pages 591-598

  Quach, Kevin ^a   Lvtvyn, Lyubov ^a   Baigent, Colin ^b   Bueti, Joe ^c   Garg, Amit X ^d   Hawley, Carmel ^e,f   Haynes, Richard ^b   Manns, Braden ^g,h   Perkovic, Vlado ⁱ   Rabbat, Christian G ^a   Wald, Ron ^j   Walsh, Michael ^a,k  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^j UNIVERSITY OF TORONTO   (Canada)

^k HAMILTON HEALTH SCIENCES   (Canada)

more..

Author keywords

adverse events; aldosterone; all cause mortality; blood pressure; cardiovascular death; end stage renal disease (ESRD); eplerenone; hemodialysis; hyperkalemia; meta analysis; Mineralocorticoid receptor antagonist (MRA); peritoneal dialysis; randomized controlled trials; spironolactone; systematic review

Indexed keywords

EPLERENONE; MINERALOCORTICOID ANTAGONIST; PLACEBO; POTASSIUM; SPIRONOLACTONE;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; GYNECOMASTIA; HEALTH CARE QUALITY; HEART FAILURE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; HYPOTENSION; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT SAFETY; PERITONEAL DIALYSIS; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; MORTALITY;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; SPIRONOLACTONE;

EID: 84975704707     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.04.011     Document Type: Article

References (30)

1. 1 Caskey, F.J., Kramer, A., Elliott, R.F., et al. Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant 26:8 (2011), 2604–2610.
2. 2 Saran, R., Li, Y., Robinson, B., et al. US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis, 66(1 suppl 1), 2015, Svii S1-S305.
3. 3 Harnett, J.D., Foley, R.N., Kent, G.M., Barre, P.E., Murray, D., Parfrey, P.S., Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47:3 (1995), 884–890.
4. 4 Brilla, C.G., Zhou, G., Matsubara, L., Weber, K.T., Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26:7 (1994), 809–820.
5. 5 Brilla, C.G., Matsubara, L.S., Weber, K.T., Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71:3 (1993), 12A–16A.
6. 6 Ezekowitz, J.A., McAlister, F.A., Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 30:4 (2009), 469–477.
7. 7 Zannad, F., McMurray, J.J., Krum, H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:1 (2011), 11–21.
8. 8 Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:15 (2014), 1383–1392.
9. 9 Juurlink, D.N., Mamdani, M.M., Lee, D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:6 (2004), 543–551.
10. 10 Higgins, J.P., Altman, D.G., Gøtzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
11. 11 DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Controll Clin Trials 7:3 (1986), 177–188.
12. 12 Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
13. 13 Guyatt, G., Oxman, A.D., Sultan, S., et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 66:2 (2013), 151–157.
14. 14 Akl, E.A., Johnston, B.C., Alonso-Coello, P., et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PloS One, 8(2), 2013, e57132.
15. 15 Matsumoto, Y., Mori, Y., Kageyama, S., et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 63:6 (2014), 528–536.
16. 16 Ito, Y., Mizuno, M., Suzuki, Y., et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 25:5 (2014), 1094–1102.
17. 17 Cornell, J.E., Mulrow, C.D., Localio, R., et al. Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med 160:4 (2014), 267–270.
18. 18 Gross, E., Rothstein, M., Dombek, S., Juknis, H.I., Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 46:1 (2005), 94–101.
19. 19 Taheri, S., Mortazavi, M., Pourmoghadas, A., Seyrafian, S., Alipour, Z., Karimi, S., A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 23:3 (2012), 507–512.
20. 20 Taheri, S., Mortazavi, M., Shahidi, S., et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 20:3 (2009), 392–397.
21. 21 Vukusich, A., Kunstmann, S., Varela, C., et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 5:8 (2010), 1380–1387.
22. 22 Walsh, M., Manns, B., Garg, A.X., et al. The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial. Clin J Am Soc Nephrol 10:9 (2015), 1602–1608.
23. 23 Yongsiri, S., Thammakumpee, J., Prongnamchai, S., et al. Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients. Ther Apher Dial 19:1 (2015), 81–86.
24. 24 Ni, X., Zhang, J., Zhang, P., et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens 16:9 (2014), 658–663.
25. 25 Ito, Y., Mizuno, M., Suzuki, Y., et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 25:5 (2014), 1094–1102.
26. 26 Thorlund, K., Imberger, G., Walsh, M., et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis–a simulation study. PloS One, 6(10), 2011, e25491.
27. 27 Schulgen, G., Olschewski, M., Krane, V., Wanner, C., Ruf, G., Schumacher, M., Sample sizes for clinical trials with time-to-event endpoints and competing risks. Contemp Clin Trials 26:3 (2005), 386–396.
28. 28 Kohagura, K., Higashiuesato, Y., Ishiki, T., et al. Plasma aldosterone in hypertensive patients on chronic hemodialysis: distribution, determinants and impact on survival. Hypertens Res 29:8 (2006), 597–604.
29. 29 Bia, M.J., DeFronzo, R.A., Extrarenal potassium homeostasis. Am J Physiol 240:4 (1981), F257–F268.
30. 30 Agarwal, R., Sinha, A.D., Pappas, M.K., Abraham, T.N., Tegegne, G.G., Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 29:3 (2014), 672–681.